CPHI Quote, Financials, Valuation and Earnings

Linike Medical Group Ltd. has a net margin of -86.16% compared to China Pharma Holdings, Inc.'s net margin of --. China Pharma Holdings, Inc.'s return on equity of -43.41% beat Linike Medical Group Ltd.'s return on equity of --.

China Pharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Linike Medical Group Ltd. has an analysts' consensus of -- which suggests that it could grow by 98674.37%. Given that Linike Medical Group Ltd. has higher upside potential than China Pharma Holdings, Inc., analysts believe Linike Medical Group Ltd. is more attractive than China Pharma Holdings, Inc..

China Pharma Holdings, Inc. has a beta of 1.198, which suggesting that the stock is 19.798% more volatile than S&P 500. In comparison Linike Medical Group Ltd. has a beta of -6.348, suggesting its less volatile than the S&P 500 by 734.788%.

China Pharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Linike Medical Group Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holdings, Inc. pays -- of its earnings as a dividend. Linike Medical Group Ltd. pays out -- of its earnings as a dividend.

China Pharma Holdings, Inc. quarterly revenues are $756.2K, which are larger than Linike Medical Group Ltd. quarterly revenues of --. China Pharma Holdings, Inc.'s net income of -$651.5K is higher than Linike Medical Group Ltd.'s net income of --. Notably, China Pharma Holdings, Inc.'s price-to-earnings ratio is -- while Linike Medical Group Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holdings, Inc. is 0.46x versus 1.95x for Linike Medical Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -86.16% compared to China Pharma Holdings, Inc.'s net margin of -304.24%. China Pharma Holdings, Inc.'s return on equity of -43.41% beat Recursion Pharmaceuticals, Inc.'s return on equity of -63.64%.

China Pharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.71 which suggests that it could grow by 82.95%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than China Pharma Holdings, Inc..

China Pharma Holdings, Inc. has a beta of 1.198, which suggesting that the stock is 19.798% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

China Pharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holdings, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

China Pharma Holdings, Inc. quarterly revenues are $756.2K, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $35.5M. China Pharma Holdings, Inc.'s net income of -$651.5K is higher than Recursion Pharmaceuticals, Inc.'s net income of -$108.1M. Notably, China Pharma Holdings, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holdings, Inc. is 0.46x versus 22.04x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tango Therapeutics, Inc. has a net margin of -86.16% compared to China Pharma Holdings, Inc.'s net margin of 29.52%. China Pharma Holdings, Inc.'s return on equity of -43.41% beat Tango Therapeutics, Inc.'s return on equity of -56.44%.

China Pharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Tango Therapeutics, Inc. has an analysts' consensus of $15.67 which suggests that it could grow by 40.63%. Given that Tango Therapeutics, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe Tango Therapeutics, Inc. is more attractive than China Pharma Holdings, Inc..

China Pharma Holdings, Inc. has a beta of 1.198, which suggesting that the stock is 19.798% more volatile than S&P 500. In comparison Tango Therapeutics, Inc. has a beta of 1.761, suggesting its more volatile than the S&P 500 by 76.144%.

China Pharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tango Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holdings, Inc. pays -- of its earnings as a dividend. Tango Therapeutics, Inc. pays out -- of its earnings as a dividend.

China Pharma Holdings, Inc. quarterly revenues are $756.2K, which are smaller than Tango Therapeutics, Inc. quarterly revenues of $53.8M. China Pharma Holdings, Inc.'s net income of -$651.5K is lower than Tango Therapeutics, Inc.'s net income of $15.9M. Notably, China Pharma Holdings, Inc.'s price-to-earnings ratio is -- while Tango Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holdings, Inc. is 0.46x versus 18.45x for Tango Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Yubo International Biotech Ltd. has a net margin of -86.16% compared to China Pharma Holdings, Inc.'s net margin of -11740.4%. China Pharma Holdings, Inc.'s return on equity of -43.41% beat Yubo International Biotech Ltd.'s return on equity of --.

China Pharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Yubo International Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that China Pharma Holdings, Inc. has higher upside potential than Yubo International Biotech Ltd., analysts believe China Pharma Holdings, Inc. is more attractive than Yubo International Biotech Ltd..

China Pharma Holdings, Inc. has a beta of 1.198, which suggesting that the stock is 19.798% more volatile than S&P 500. In comparison Yubo International Biotech Ltd. has a beta of 0.799, suggesting its less volatile than the S&P 500 by 20.114%.

China Pharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Yubo International Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holdings, Inc. pays -- of its earnings as a dividend. Yubo International Biotech Ltd. pays out -- of its earnings as a dividend.

China Pharma Holdings, Inc. quarterly revenues are $756.2K, which are larger than Yubo International Biotech Ltd. quarterly revenues of --. China Pharma Holdings, Inc.'s net income of -$651.5K is lower than Yubo International Biotech Ltd.'s net income of -$310.2K. Notably, China Pharma Holdings, Inc.'s price-to-earnings ratio is -- while Yubo International Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holdings, Inc. is 0.46x versus 12.99x for Yubo International Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.